Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVM-1118 + nivolumab
- Development stage
- Unknown
- Lead developer
- TaiRx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**CVM-1118 + nivolumab** is an investigational combination therapy for advanced cancers, currently in clinical trials for unresectable hepatocellular carcinoma (HCC). CVM-1118 (foslinanib) is a novel small molecule targeting tumor cell survival and vasculogenic mimicry (VM) by binding to TNF receptor associated protein 1 (TRAP1, also known as Hsp75), inducing mitochondrial apoptosis, arresting cell cycle at G2/M phase, and inhibiting VM network formation[1][2][4]. CVM-1118 is rapidly metabolized to its active metabolite CVM-1125. Nivolumab is a human monoclonal IgG4 kappa antibody that acts as a checkpoint inhibitor targeting PD-1, enhancing T-cell anti-tumor responses. The combination aims to leverage the complementary mechanisms of apoptosis induction and immune checkpoint inhibition for improved anti-tumor efficacy. Developed and tested by TaiRx, CVM-1118 is supported by favorable early safety and efficacy data in advanced HCC compared to other regimens such as atezolizumab plus bevacizumab[1][3].
- Brand names
- Opdivo
- Other names
- CVM-1118 + nivolumab
02
Targets
TRAP1 (Tumor necrosis factor receptor-associated protein 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on CVM-1118 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVM-1118 + nivolumab.